Crohn’s disease as an immunodeficiency

References

• Rogler G, Andus T. Cytokines in inflammatory bowel disease. World J. Surg.22(4), 382–389 (1998).
   PubMed Web of Science ®Google Scholar
• Abraham C, Cho JH. Inflammatory bowel disease. N. Engl. J. Med.361(21), 2066–2078 (2009).
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel. Dis.12(Suppl. 1), S3–S9 (2006).
   PubMed Web of Science ®Google Scholar
• Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut58(8), 1152–1167 (2009).
   PubMed Web of Science ®Google Scholar
• Neurath MF. IL-23: a master regulator in Crohn disease. Nat. Med.13(1), 26–28 (2007).
   PubMed Web of Science ®Google Scholar
• Boden EK, Snapper SB. Regulatory T cells in inflammatory bowel disease. Curr. Opin. Gastroenterol.24733–24741 (2008).
   Google Scholar
• Peyrin-Biroulet L, Deltenre P, Ardizzone S et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am. J. Gastroenterol.104(8), 2089–2096 (2009).
   PubMed Web of Science ®Google Scholar
• Rahman FZ, Marks DJ, Hayee BH et al. Phagocyte dysfunction and inflammatory bowel disease. Inflamm. Bowel. Dis.14(10), 1443–1452 (2008).
   PubMedGoogle Scholar
• Marks DJ, Miyagi K, Rahman FZ et al. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn’s disease. Am. J. Gastroenterol.104(1), 117–124 (2009).
   PubMed Web of Science ®Google Scholar
• Segal AW. How neutrophils kill microbes. Annu. Rev. Immunol.23197–23223 (2005).
   Google Scholar
• Segal AW, Loewi G. Neutrophil dysfunction in Crohn’s disease. Lancet2(7979), 219–221 (1976).
   PubMed Web of Science ®Google Scholar
• Marks DJ, Harbord MW, MacAllister R et al. Defective acute inflammation in Crohn’s disease: a clinical investigation. Lancet367(9511), 668–678 (2006).
   PubMed Web of Science ®Google Scholar
• Smith AM, Rahman FZ, Hayee B et al. Disordered macrophage cytokine secretion underlies impaired acute inflammation and bacterial clearance in Crohn’s disease. J. Exp. Med.206(9), 1883–1897 (2009).
   PubMed Web of Science ®Google Scholar
• Li Y, Karlin A, Loike JD et al. A critical concentration of neutrophils is required for effective bacterial killing in suspension. Proc. Natl Acad. Sci. USA99(12), 8289–8294 (2002).
   PubMed Web of Science ®Google Scholar
• Li Y, Karlin A, Loike JD et al. Determination of the critical concentration of neutrophils required to block bacterial growth in tissues. J. Exp. Med.200(5), 613–622 (2004).
   PubMed Web of Science ®Google Scholar
• Sewell GW, Marks DJ, Segal AW. The immunopathogenesis of Crohn’s disease: a three-stage model. Curr. Opin. Immunol.21(5), 506–513 (2009).
   PubMed Web of Science ®Google Scholar
• Adams DO. The granulomatous inflammatory response. A review. Am. J. Pathol.84(1), 164–192 (1976).
   PubMed Web of Science ®Google Scholar
• Kyle J. Urinary complications of Crohn’s disease. World J. Surg.4(2), 153–160 (1980).
   PubMedGoogle Scholar
• Porter CK, Tribble DR, Aliaga PA et al. Infectious gastroenteritis and risk of developing inflammatory bowel disease. Gastroenterology135(3), 781–786 (2008).
   PubMed Web of Science ®Google Scholar
• Myrelid P, Olaison G, Sjodahl R et al. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn’s disease. Dis. Colon Rectum52(8), 1387–1394 (2009).
   PubMed Web of Science ®Google Scholar
• Hildebrand H, Malmborg P, Askling J et al. Early-life exposures associated with antibiotic use and risk of subsequent Crohn’s disease. Scand. J. Gastroenterol.43(8), 961–966 (2008).
   PubMed Web of Science ®Google Scholar
• Farthing MJ. Bugs and the gut: an unstable marriage. Best. Pract. Res. Clin. Gastroenterol.18(2), 233–239 (2004).
   PubMedGoogle Scholar
• Diaz PI, Chalmers NI, Rickard AH et al. Molecular characterization of subject-specific oral microflora during initial colonization of enamel. Appl. Environ. Microbiol.72(4), 2837–2848 (2006).
   PubMed Web of Science ®Google Scholar
• Darfeuille-Michaud A, Boudeau J, Bulois P et al. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology127(2), 412–421 (2004).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ et al. The safety profile of infliximab in patients with Crohn’s disease: the Mayo clinic experience in 500 patients. Gastroenterology126(1), 19–31 (2004).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin. Gastroenterol. Hepatol.4(5), 621–630 (2006).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Loftus EV Jr, Tremaine WJ et al. Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am. J. Gastroenterol.99(5), 878–883 (2004).
   PubMed Web of Science ®Google Scholar
• Hofmann A, Beaulieu Y, Bernard F et al. Fulminant legionellosis in two patients treated with infliximab for Crohn’s disease: case series and literature review. Can. J. Gastroenterol.23(12), 829–833 (2009).
   PubMedGoogle Scholar
• Warner EA, Moldawer LL. Using innate immunity to characterize the host response to microbial invasion in severe sepsis. Future Microbiol.3177–3189 (2008).
   Google Scholar
• Hayee BH, Sewell G, Rahman FZ, Bloom SL, Smith AM, Segal AW. Differential bacterial clearance and cytokine secretion by macrophages explains localisation of Crohn’s disease to the gut. Gut59(4 Suppl. 1), A61 (2010).
   Google Scholar
• Morain CO, Segal AA, Walker D et al. Abnormalities of neutrophil function do not cause the migration defect in Crohn’s disease. Gut22(10), 817–822 (1981).
   PubMed Web of Science ®Google Scholar
• Zarbock A, Ley K. Neutrophil adhesion and activation under flow. Microcirculation16(1), 31–42 (2009).
   PubMed Web of Science ®Google Scholar
• Zarbock A, Ley K. Mechanisms and consequences of neutrophil interaction with the endothelium. Am. J. Pathol.172(1), 1–7 (2008).
   PubMed Web of Science ®Google Scholar
• Arai F, Takahashi T, Furukawa K et al. Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn’s disease. Dig. Dis. Sci.43(9), 2071–2079 (1998).
   PubMed Web of Science ®Google Scholar
• Murch SH, Braegger CP, Walker-Smith JA et al. Location of tumour necrosis factor α by immunohistochemistry in chronic inflammatory bowel disease. Gut34(12), 1705–1709 (1993).
   PubMed Web of Science ®Google Scholar
• Mazzucchelli L, Hauser C, Zgraggen K et al. Expression of interleukin-8 gene in inflammatory bowel disease is related to the histological grade of active inflammation. Am. J. Pathol.144(5), 997–1007 (1994).
   PubMed Web of Science ®Google Scholar
• Smythies LE, Maheshwari A, Clements R et al. Mucosal IL-8 and TGF-β recruit blood monocytes: evidence for cross-talk between the lamina propria stroma and myeloid cells. J. Leukoc. Biol.80(3), 492–499 (2006).
   PubMed Web of Science ®Google Scholar
• Zhou L, Braat H, Faber KN et al. Monocytes and their pathophysiological role in Crohn’s disease. Cell Mol. Life Sci.66(2), 192–202 (2009).
   PubMedGoogle Scholar
• Casanova JL, Abel L. Revisiting Crohn’s disease as a primary immunodeficiency of macrophages. J. Exp. Med.206(9), 1839–1843 (2009).
   PubMedGoogle Scholar
• Adams DO, Hamilton TA. The activated macrophage and granulomatous inflammation. Curr. Top. Pathol.79, 151–167 (1989).
   PubMedGoogle Scholar
• Naito Y, Takagi T, Handa O et al. Enhanced intestinal inflammation induced by dextran sulfate sodium in tumor necrosis factor-α deficient mice. J. Gastroenterol. Hepatol.18(5), 560–569 (2003).
   PubMed Web of Science ®Google Scholar
• Wong M, Ziring D, Korin Y et al. TNFa blockade in human diseases: mechanisms and future directions. Clin. Immunol.126(2), 121–136 (2008).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology121(5), 1088–1094 (2001).
   PubMed Web of Science ®Google Scholar
• Palmer CD, Rahman FZ, Sewell GW et al. Diminished macrophage apoptosis and reactive oxygen species generation after phorbol ester stimulation in Crohn’s disease. PLoS. One.4(11), e7787 (2009).
   Google Scholar
• Brannigan AE, O’Connell PR, Hurley H et al. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock13(5), 361–366 (2000).
   PubMed Web of Science ®Google Scholar
• Boirivant M, Marini M, Di FG et al. Lamina propria T cells in Crohn’s disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology116(3), 557–565 (1999).
   PubMed Web of Science ®Google Scholar
• Yazisiz V, Avci AB, Erbasan F et al. Development of Crohn’s disease following anti-tumour necrosis factor therapy (etanercept). Colorectal Dis.10(9), 953–954 (2008).
   PubMed Web of Science ®Google Scholar
• Charach G, Grosskopf I, Weintraub M. Development of Crohn’s disease in a patient with multiple sclerosis treated with copaxone. Digestion77(3–4), 198–200 (2008).
   PubMedGoogle Scholar
• Wehkamp J, Schmid M, Fellermann K et al. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn’s disease. J. Leukoc. Biol.77(4), 460–465 (2005).
   PubMed Web of Science ®Google Scholar
• Zeissig S, Burgel N, Gunzel D et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut56(1), 61–72 (2007).
   PubMed Web of Science ®Google Scholar
• Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology132(4), 1359–1374 (2007).
   PubMed Web of Science ®Google Scholar
• Froy O. Regulation of mammalian defensin expression by Toll-like receptor-dependent and independent signalling pathways. Cell Microbiol.7(10), 1387–1397 (2005).
   PubMed Web of Science ®Google Scholar
• Hollander D, Vadheim CM, Brettholz E et al. Increased intestinal permeability in patients with Crohn’s disease and their relatives. A possible etiologic factor. Ann. Intern. Med.105(6), 883–885 (1986).
   PubMed Web of Science ®Google Scholar
• Barrett JC, Hansoul S, Nicolae DL et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet.40(8), 955–962 (2008).
   PubMed Web of Science ®Google Scholar
• Buisine MP, Desreumaux P, Leteurtre E et al. Mucin gene expression in intestinal epithelial cells in Crohn’s disease. Gut49(4), 544–551 (2001).
   PubMed Web of Science ®Google Scholar
• Beatty PL, Plevy SE, Sepulveda AR et al. Cutting edge: transgenic expression of human MUC1 in IL-10-/- mice accelerates inflammatory bowel disease and progression to colon cancer. J. Immunol.179(2), 735–739 (2007).
   PubMedGoogle Scholar
• van der Sluis M, De Koning BA, De Bruijn AC et al.Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology131(1), 117–129 (2006).
   PubMed Web of Science ®Google Scholar
• Silva MA. Intestinal dendritic cells and epithelial barrier dysfunction in Crohn’s disease. Inflamm. Bowel. Dis.15(3), 436–453 (2009).
   PubMedGoogle Scholar
• Lapaquette P, Glasser AL, Huett A et al. Crohn’s disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol.12(1), 99–113 (2010).
   PubMed Web of Science ®Google Scholar
• Glasser AL, Boudeau J, Barnich N et al. Adherent invasive Escherichia coli strains from patients with Crohn’s disease survive and replicate within macrophages without inducing host cell death. Infect. Immun.69(9), 5529–5537 (2001).
   PubMed Web of Science ®Google Scholar
• Stadnyk AW. Cytokine production by epithelial cells. FASEB J.8(13), 1041–1047 (1994).
   PubMed Web of Science ®Google Scholar
• Qin J, Li R, Raes J et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature464(4), 59–68 (2010).
   PubMed Web of Science ®Google Scholar
• Manichanh C, Rigottier-Gois L, Bonnaud E et al. Reduced diveristy of fecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut55205–55211 (2006).
   Google Scholar
• Ott SJ, Musfeldt M, Wenderoth DF et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut53(5), 685–693 (2004).
   PubMed Web of Science ®Google Scholar
• Lindsay JO, Whelan K, Stagg AJ et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut55(3), 348–355 (2006).
   PubMed Web of Science ®Google Scholar
• Sokol H, Pigneur B, Watterlot L et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl Acad. Sci. USA105(43), 16731–16736 (2008).
   PubMed Web of Science ®Google Scholar
• Martin HM, Campbell BJ, Hart CA et al. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology127(1), 80–93 (2004).
   PubMed Web of Science ®Google Scholar
• Mpofu CM, Campbell BJ, Subramanian S et al. Microbial mannan inhibits bacterial killing by macrophages: a possible pathogenic mechanism for Crohn’s disease. Gastroenterology133(5), 1487–1498 (2007).
   PubMedGoogle Scholar
• Subramanian S, Roberts CL, Hart CA et al. Replication of colonic Crohn’s disease mucosal Escherichia coli isolates within macrophages and their susceptibility to antibiotics. Antimicrob. Agents Chemother.52(2), 427–434 (2008).
   PubMed Web of Science ®Google Scholar
• Vantrappen G, Ponette E, Geboes K et al. Yersinia enteritis and enterocolitis: gastroenterological aspects. Gastroenterology72(2), 220–227 (1977).
   PubMed Web of Science ®Google Scholar
• Isaacs KL, Sartor RB. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol. Clin. North Am.33(2), 335–345 (2004).
   PubMed Web of Science ®Google Scholar
• Swift GL, Srivastava ED, Stone R et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn’s disease. Gut35(3), 363–368 (1994).
   PubMedGoogle Scholar
• Bridger S, Lee JC, Bjarnason I et al. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn’s disease and non-smokers develop ulcerative colitis. Gut51(1), 21–25 (2002).
   PubMed Web of Science ®Google Scholar
• Lindberg E, Tysk C, Andersson K et al. Smoking and inflammatory bowel disease. A case control study. Gut29(3), 352–357 (1988).
   PubMed Web of Science ®Google Scholar
• Lindberg E, Jarnerot G, Huitfeldt B. Smoking in Crohn’s disease: effect on localisation and clinical course. Gut33(6), 779–782 (1992).
   PubMed Web of Science ®Google Scholar
• Sher ME, Bank S, Greenberg R et al. The influence of cigarette smoking on cytokine levels in patients with inflammatory bowel disease. Inflamm. Bowel. Dis.5(2), 73–78 (1999).
   PubMed Web of Science ®Google Scholar
• Aldhous MC, Prescott RJ, Roberts S et al. Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in inflammatory bowel disease? Inflamm. Bowel. Dis.14(11), 1469–1482 (2008).
   PubMed Web of Science ®Google Scholar
• Sopori M. Effects of cigarette smoke on the immune system. Nat. Rev. Immunol.2(5), 372–377 (2002).
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Bjerrum JT, Csillag C et al. Influence of smoking on colonic gene expression profile in Crohn’s disease. PLoS One4(7), e6210 (2009).
   Google Scholar
• de Jonge WJ, Ulloa L. The α7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br. J. Pharmacol.151, 915–929 (2007).
   PubMed Web of Science ®Google Scholar
• Hamano R, Takahashi HK, Iwagaki H et al. Stimulation of α7 nicotinic acetylcholine receptor inhibits CD14 and the Toll-like receptor 4 expression in human monocytes. Shock26, 358–364 (2006).
   PubMed Web of Science ®Google Scholar
• Cope GF, Heatley RV, Kelleher JK. Smoking and colonic mucus in ulcerative colitis. Br. Med. J. (Clin. Res. Ed)293(6545), 481 (1986).
   PubMed Web of Science ®Google Scholar
• Issekutz AC. Vascular responses during acute neutrophilic inflammation. Their relationship to in vivo neutrophil emigration. Lab. Invest.45(5), 435–441 (1981).
   PubMedGoogle Scholar
• Issekutz AC. Effect of vasoactive agents on polymorphonuclear leukocyte emigration in vivo. Lab. Invest.45(3), 234–240 (1981).
   PubMedGoogle Scholar
• De Bruin AF, Schouten SB, de Kort PP et al. The impact of chronic smoking on rectal mucosal blood flow. Tech. Coloproctol.13(4), 269–272 (2009).
   PubMedGoogle Scholar
• Srivastava ED, Russell MA, Feyerabend C et al. Effect of ulcerative colitis and smoking on rectal blood flow. Gut31(9), 1021–1024 (1990).
   PubMed Web of Science ®Google Scholar
• Shoda R, Matsueda K, Yamato S et al. Epidemiologic analysis of Crohn disease in Japan: increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am. J. Clin. Nutr.63(5), 741–745 (1996).
   PubMed Web of Science ®Google Scholar
• Bamba T, Shimoyama T, Sasaki M et al. Dietary fat attenuates the benefits of an elemental diet in active Crohn’s disease: a randomized, controlled trial. Eur. J. Gastroenterol. Hepatol.15(2), 151–157 (2003).
   PubMedGoogle Scholar
• Gassull MA, Fernandez-Banares F, Cabre E et al. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn’s disease: results of a double blind randomised multicentre European trial. Gut51(2), 164–168 (2002).
   PubMed Web of Science ®Google Scholar
• Shoda R, Matsueda K, Yamato S et al. Therapeutic efficacy of N-3 polyunsaturated fatty acid in experimental Crohn’s disease. J. Gastroenterol.30(Suppl. 8), 98–101 (1995).
   PubMedGoogle Scholar
• Lewis R, Gorbach S. Modification of bile acids by intestinal bacteria. Arch. Intern. Med.130(4), 545–549 (1972).
   PubMedGoogle Scholar
• Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res.47(2), 241–259 (2006).
   PubMed Web of Science ®Google Scholar
• Vantrappen G, Ghoos Y, Rutgeerts P et al. Bile acid studies in uncomplicated Crohn’s disease. Gut18(9), 730–735 (1977).
   PubMed Web of Science ®Google Scholar
• Pereira SP, Bain IM, Kumar D et al. Bilecomposition in inflammatory bowel disease: ileal disease and colectomy, but not colitis, induce lithogenic bile. Aliment. Pharmacol. Ther.17(7), 923–933 (2003).
   PubMedGoogle Scholar
• Lapidus A, Akerlund JE, Einarsson C. Gallbladder bile composition in patients with Crohn ‘s disease. World J. Gastroenterol.12(1), 70–74 (2006).
   PubMedGoogle Scholar
• Zhao DL, Hirst BH. Bile salt-induced increases in duodenal brush-border membrane proton permeability, fluidity, and fragility. Dig. Dis. Sci.35(5), 589–595 (1990).
   PubMedGoogle Scholar
• Zhao DL, Hirst BH. Comparison of bile salt perturbation of duodenal and jejunal isolated brush-border membranes. Digestion47(4), 200–207 (1990).
   PubMedGoogle Scholar
• Merrett MN, Owen RW, Jewell DP. Ileal pouch dialysate is cytotoxic to epithelial cell lines, but not to CaCo-2 monolayers. Eur. J. Gastroenterol. Hepatol.9(12), 1219–1226 (1997).
   PubMedGoogle Scholar
• Fasano A, Verga MC, Raimondi F et al. Effects of deconjugated bile acids on electrolyte and nutrient transport in the rabbit small intestine in vitro. J. Pediatr. Gastroenterol. Nutr.18(3), 327–333 (1994).
   PubMedGoogle Scholar
• Raimondi F, Santoro P, Barone MV et al. Bile acids modulate tight junction structure and barrier function of Caco-2 monolayers via EGFR activation. Am. J. Physiol. Gastrointest. Liver Physiol.294(4), G906–G913 (2008).
   PubMed Web of Science ®Google Scholar
• O’Connor CJ, Wallace RG, Iwamoto K et al. Bile salt damage of egg phosphatidylcholine liposomes. Biochim. Biophys. Acta817(1), 95–102 (1985).
   PubMed Web of Science ®Google Scholar
• Powell AA, LaRue JM, Batta AK et al. Bile acid hydrophobicity is correlated with induction of apoptosis and/or growth arrest in HCT116 cells. Biochem. J.356(Pt 2), 481–486 (2001).
   PubMed Web of Science ®Google Scholar
• Gitter AH, Bendfeldt K, Schulzke JD et al. Leaks in the epithelial barrier caused by spontaneous and TNF-α-induced single-cell apoptosis. FASEB J.14(12), 1749–1753 (2000).
   PubMed Web of Science ®Google Scholar
• Lin JA, Watanabe J, Rozengurt N et al. Atherogenic diet causes lethal ileo-ceco-colitis in cyclooxygenase-2 deficient mice. Prostaglandins Other Lipid Mediat.84(3–4), 98–107 (2007).
   PubMedGoogle Scholar
• Bernstein H, Holubec H, Bernstein C et al. Unique dietary-related mouse model of colitis. Inflamm. Bowel. Dis.12(4), 278–293 (2006).
   PubMedGoogle Scholar
• Lashner BA, Loftus EV Jr. True or false? The hygiene hypothesis for Crohn’s disease. Am. J. Gastroenterol.101(5), 1003–1004 (2006).
   PubMed Web of Science ®Google Scholar
• Elliott DE, Urban JF Jr, Argo CK et al. Does the failure to acquire helminthic parasites predispose to Crohn’s disease? FASEB J.14(12), 1848–1855 (2000).
   PubMed Web of Science ®Google Scholar
• Summers RW, Elliott DE, Urban JF Jr et al. Trichuris suis therapy in Crohn’s disease. Gut54(1), 87–90 (2005).
   PubMed Web of Science ®Google Scholar
• Elliott DE, Urban JF Jr, Argo CK et al. Does the failure to acquire helminthic parasites predispose to Crohn’s disease? FASEB J.14(12), 1848–1855 (2000).
   PubMed Web of Science ®Google Scholar
• Stasi C, Orlandelli E. Role of the brain–gut axis in the pathophysiology of Crohn’s disease. Dig. Dis.26(2), 156–166 (2008).
   PubMedGoogle Scholar
• Zinyama RB, Bancroft GJ, Sigola LB. Adrenaline suppression of the macrophage nitric oxide response to lipopolysaccharide is associated with differential regulation of tumour necrosis factor-α and interleukin-10. Immunology104(4), 439–446 (2001).
   PubMed Web of Science ®Google Scholar
• Li CY, Chou TC, Lee CH et al. Adrenaline inhibits lipopolysaccharide-induced macrophage inflammatory protein-1 α in human monocytes: the role of β-adrenergic receptors. Anesth. Analg.96(2), 518–523 (2003).
   PubMedGoogle Scholar
• Tracey KJ. Reflex control of immunity. Nat. Rev. Immunol.9(6), 418–428 (2009).
   PubMed Web of Science ®Google Scholar
• Young MR, Matthews JP. Serotonin regulation of T-cell subpopulations and of macrophage accessory function. Immunology84(1), 148–152 (1995).
   PubMedGoogle Scholar
• Sirota M, Schaub MA, Batzoglou S et al. Autoimmune disease classification by inverse association with SNP alleles. PLoS Genet.5(12), e1000792 (2009).
   PubMedGoogle Scholar
• Manolio TA, Collins FS, Cox NJ et al. Finding the missing heritability of complex diseases. Nature461(7265), 747–753 (2009).
   PubMed Web of Science ®Google Scholar
• Cuthbert AP, Fisher SA, Mirza MM et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology122(4), 867–874 (2002).
   PubMed Web of Science ®Google Scholar
• Hampe J, Cuthbert A, Croucher PJ et al. Association between insertion mutation in NOD2 gene and Crohn’s disease in German and British populations. Lancet357(9272), 1925–1928 (2001).
   PubMed Web of Science ®Google Scholar
• Hampe J, Franke A, Rosenstiel P et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet.39(2), 207–211 (2007).
   PubMed Web of Science ®Google Scholar
• Van LJ, Russell RK, Nimmo ER et al. Autophagy gene ATG16L1 influences susceptibility and disease location but not childhood-onset in Crohn’s disease in Northern Europe. Inflamm. Bowel Dis.14(3), 338–346 (2008).
   PubMedGoogle Scholar
• Cooney R, Jewell D. The genetic basis of inflammatory bowel disease. Dig. Dis.27(4), 428–442 (2009).
   PubMed Web of Science ®Google Scholar
• Cooney R, Baker J, Brain O et al. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat. Med.16(1), 90–97 (2010).
   PubMed Web of Science ®Google Scholar
• Travassos LH, Carneiro LA, Ramjeet M et al. Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the plasma membrane at the site of bacterial entry. Nat. Immunol.11(1), 55–62 (2010).
   PubMed Web of Science ®Google Scholar
• Fujita N, Saitoh T, Kageyama S et al. Differential involvement of Atg16L1 in Crohn disease and canonical autophagy: analysis of the organization of the Atg16L1 complex in fibroblasts. J. Biol. Chem.284(47), 32602–32609 (2009).
   PubMed Web of Science ®Google Scholar
• Saitoh T, Fujita N, Jang MH et al. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1β production. Nature456(7219), 264–268 (2008).
   PubMed Web of Science ®Google Scholar
• Pauleau AL, Murray PJ. Role of Nod2 in the response of macrophages to Toll-like receptor agonists. Mol. Cell. Biol.23(21), 7531–7539 (2003).
   PubMed Web of Science ®Google Scholar
• Kobayashi KS, Chamaillard M, Ogura Y et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science307(5710), 731–734 (2005).
   PubMed Web of Science ®Google Scholar
• Kuballa P, Huett A, Rioux JD et al. Impaired autophagy of an intracellular pathogen induced by a Crohn’s disease associated ATG16L1 variant. PLoS. One3(10), e3391 (2008).
   PubMed Web of Science ®Google Scholar
• Hudspith B, Rayment N, Prescott N et al.In vitro responses of macrophages to E. coli challenge in Crohn’s disease. Gastroenterology136(5 (Suppl. 1), A250 (2009).
   Google Scholar
• Buchmeier NA, Heffron F. Intracellular survival of wild-type Salmonella typhimurium and macrophage-sensitive mutants in diverse populations of macrophages. Infect. Immun.57(1), 1–7 (1989).
   PubMed Web of Science ®Google Scholar
• Glasser AL, Boudeau J, Barnich N et al. Adherent invasive Escherichia coli strains from patients with Crohn’s disease survive and replicate within macrophages without inducing host cell death. Infect. Immun.69(9), 5529–5537 (2001).
   PubMed Web of Science ®Google Scholar
• Lapaquette P, Glasser AL, Huett A et al. Crohn’s disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol.12(1), 99–113 (2010).
   PubMed Web of Science ®Google Scholar
• Fujita N, Saitoh T, Kageyama S et al. Differential involvement of Atg16L1 in Crohn disease and canonical autophagy: analysis of the organization of the Atg16L1 complex in fibroblasts. J. Biol. Chem.284(47), 32602–32609 (2009).
   PubMed Web of Science ®Google Scholar
• Takeda K, Clausen BE, Kaisho T et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity10(1), 39–49 (1999).
   PubMed Web of Science ®Google Scholar
• Takeda K, Noguchi K, Shi W et al. Targeted disruption of the mouse Stat3 gene leads to early embryonic lethality. Proc. Natl Acad. Sci. USA94(8), 3801–3804 (1997).
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Kweon MN, Kuwata H et al. Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J. Clin. Invest111(9), 1297–1308 (2003).
   PubMed Web of Science ®Google Scholar
• Matsukawa A, Takeda K, Kudo S et al. Aberrant inflammation and lethality to septic peritonitis in mice lacking STAT3 in macrophages and neutrophils. J. Immunol.171(11), 6198–6205 (2003).
   PubMed Web of Science ®Google Scholar
• Kuhl AA, Kakirman H, Janotta M et al. Aggravation of different types of experimental colitis by depletion or adhesion blockade of neutrophils. Gastroenterology133(6), 1882–1892 (2007).
   PubMed Web of Science ®Google Scholar
• van Heel DA, Udalova IA, De Silva AP et al. Inflammatory bowel disease is associated with a TNF polymorphism that affects an interaction between the OCT1 and NFκB transcription factors. Hum. Mol. Genet.11(11), 1281–1289 (2002).
   PubMed Web of Science ®Google Scholar
• Okazaki T, Wang MH, Rawsthorne P et al. Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn’s disease risk in a population-based case–control study: evidence of gene–gene interactions. Inflamm. Bowel Dis.14(11), 1528–1541 (2008).
   PubMed Web of Science ®Google Scholar
• Ansari A, Hassan C, Duley J et al. Thiopurine methyltransferase activity and the use of azathioprine in inflammatory bowel disease. Aliment. Pharmacol. Ther.16(10), 1743–1750 (2002).
   PubMed Web of Science ®Google Scholar
• Farrell RJ, Murphy A, Long A et al. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology118(2), 279–288 (2000).
   PubMed Web of Science ®Google Scholar
• Lees CW, Satsangi J. Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. Expert. Rev. Gastroenterol. Hepatol.3(5), 513–534 (2009).
   PubMedGoogle Scholar
• Csillag C, Nielsen OH, Borup R et al. Clinical phenotype and gene expression profile in Crohn’s disease. Am. J. Physiol Gastrointest. Liver Physiol.292(1), G298–G304 (2007).
   Google Scholar
• Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn’s disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum. Mol. Genet.10(5), 445–456 (2001).
   PubMed Web of Science ®Google Scholar
• Dieckgraefe BK, Korzenik JR, Anant S. Growth factors as treatment options for intestinal inflammation. Ann. NY Acad. Sci.1072, 300–306 (2006).
   PubMedGoogle Scholar
• Dejaco C, Lichtenberger C, Miehsler W et al. An open-label pilot study of granulocyte colony-stimulating factor for the treatment of severe endoscopic postoperative recurrence in Crohn’s disease. Digestion68(2–3), 63–70 (2003).
   PubMedGoogle Scholar